David Glahn, PhD, Professor of Psychiatry at Yale, has received the Joel Elkes Research Award from the American College of Neuropsychopharmacology (ACNP).
The award was presented on December 5 at the 55th annual meeting of the ACNP in Hollywood, Fla. It was given in recognition of Glahn’s outstanding clinical contributions to neuropsychopharmacology.
Glahn was nominated for the award by John H. Krystal, Robert L. McNeil, Jr. Professor of Translational Research and Chair of the Yale Department of Psychiatry. Krystal called Glahn a “strikingly original and productive scientist,” a “dynamic teacher,” and “an outstanding mentor.”
Glahn has published over 200 papers and reviews in leading scientific journals. He leads a number of research grants funded by the National Institutes of Health, and has played a seminal role in building and leading imaging-genomics consortia to advance the analytic methods for the enormous datasets involved in whole genome sequencing.
According to a news release from the ACNP, “The power of Dr. Glahn’s approach is that he uses function to search for structure. That is, he utilizes his deep knowledge of cognitive neuroscience to nominate potential biomarkers, which can then be studied in large pedigree cohorts to assess heritability, reveal disease associations, and identify putative risk genes. This approach helps to ensure that identified risk genes are likely to have a meaningful impact on the daily functioning of the individual, eliminating the need to conduct a post-hoc search to ascribe function.”
Glahn is Director of the Affective Disorders and Psychosis (ADAPTING) Laboratory at the Olin Neuropsychiatric Research Center, Institute of Living, Hartford Hospital.
He is a Section Editor for the journal Human Brain Mapping and is on the editorial board of three other professional journals. He is a Fellow in the ACNP, and has received several other professional honors, including the A.E. Bennett Award of the Society of Biological Psychiatry.